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Nephroprotective drugs from
traditionally used Aboriginal
medicinal plants
To the Editor: The recent article by Farese et al.1 sheds light
on a very important source area of drug development,
medicinal plants. People in different cultures, all over the
world, have used medicinal plants for a number of diseases.
One such traditional medicine system is that of the Canadian
Aboriginals. This system has been practiced for centuries and
encompasses treating the whole person through mind, body,
and spirit. Medicinal plants make up the most important tool
in curing a disease. Table 1 lists selected plants used by
Aboriginal tribes all over Canada for kidney diseases. Mostly,
these are used for diuresis, renal stones and cleansing the
kidneys. Plants have also been a major source of new drugs
since the inception of modern pharmacology.2 According to a
survey, one-third of all the newly approved compounds are
derived from plants.2 A brief review of the literature shows
different plants being effective in preventing/treating renal
diseases either in animal models or in clinical trials.3,4 Some
renal conditions reported to respond to plant therapy are
glomerulonephritis, IgA nephropathy, membranous nephro-
pathy, glomerulosclerosis, immune complex nephritis, ne-
phrotic syndrome, lupus, tubulointerstitial nephritis, chronic
allograft nephropathy, kidney stones, etc.3,4 Some pharmaco-
logical characteristics seen in plants that may contribute in
the above-mentioned conditions are antiinﬂammation; anti-
oxidation; diuresis; immunomodulation; prevention of acute
allograft rejection and drug-induced nephrotoxicity; reduc-
tion in proteinuria, renal interstitial ﬁbrosis, renal ischemia/
reperfusion injury, tubular and mesangial cell proliferation,
blood lipid levels, blood pressure, lipid peroxidation,
apoptosis, renal necrosis, and calcium oxalate crystal
aggregation; and stimulation of renal repair mechanisms,
RNA and protein synthesis.3,4 Continued efforts are required
to identify and develop traditionally used medicinal plants
in renal diseases so that more effective treatments are
available from plants that have been known for their efﬁcacy
for hundreds of years.
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Table 1 | List of selected Aboriginal medicinal plants traditionally used in kidney diseases
Scientific name
Common name
(plant type) Family Part used
Traditional use
(preparation) Habitat (tribe)
Acer
pensylvanicum
Striped maple (tree) Aceraceae Bark Diuretic (bark tea) NB, NS, PE, QC, ON
(Penobscot, Micmac)
Arctostaphylos
uva-ursi
Bearberry (shrub) Ericaceae Leaf Diuretic (tea of leaves) All of Canada (Algonquin,
Blackfoot, Micmac, Salish)
Cornus
canadensis
Bunchberry (herb) Cornaceae Whole plant Kidney problems (drinking
steeped plant)
All of Canada (Micmac)
Cucurbita sp. Squash (vine) Cucurbitaceae Seed Diuretic (chewing seeds,
seeds pulverized and taken
with water)
ON, QC (Chippewa, Plains
Indians)
Juniperus
cummunis
Juniper (tree) Cupressaceae Twig, berry Kidney problems (twig and
berry tea)
All of Canada (Gitxsan,
Blackfoot, Micmac, Cree)
Epigaea repens Trailing arbutus (shrub) Ericaceaae Leaf Kidney stones (infusion of
leaves)
Southern Canada
(Algonquin, Iroquois)
Larix laricina Tamarack (tree) Pinaceae Gum Kidney problems (chewing
of gum)
BC, ON, QC, Atlantic Canada
(Cree, Ojibwe, Chippewa)
Ledum
groenlandicum
Labrador tea (Shrub) Ericaceae Leaf Kidney problems (leaves
infusion)
All of Canada (Cree, Micmac)
Medeola
virginiana
Cucumber root (herb) Liliaceae Crushed dried
berry and leaf,
root
Diuretic (berry and leaf
infusion; chewing root)
NS, NB, QC (Iroquois)
Pinus strobus White pine (tree) Pinaceae Bark, needle,
twig
Kidney and urinary
problems (tea of plant parts)
Atlantic Canada, QC, ON, MB
(Algonquin, Iroquois,
Ojibwe, Micmac)
Sarracenia
purpurea
Purple pitcher plant
(herb)
Sarraceniaceae Root Kidney problems (drinking
steeped root)
Southern Canada (Micmac)
Abbreviations: BC, British Columbia; MB, Manitoba; NB, New Brunswick; NS, Nova Scotia; ON, Ontario; PE, Prince Edward Island; QC, Quebec.
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The Authors Reply: We agree with the commentary of
Drs Ghayur and Janssen regarding the importance of
medicinal plants in the treatment of many diseases in
different cultures and ages.1 Moreover, today, medicinal
plants still represent a vast source of new chemical molecules
that continuously promote drug research. However, the
uncontrolled resurgence of these ‘natural products’ observed
today, and promoted by thousands of Internet sites, needs
several caveats: (1) These remedies are often assumed to be
safe (because they are natural). (2) Potential risks associated
with such treatments are only poorly studied or reported. (3)
These remedies are mostly not under the control of a
regulatory system that guarantees a high-quality manufacture
of the product.
The adverse effects of such products may involve direct
risks such as dose-dependent toxicity, idiosyncratic reactions,
teratogenicity, and mutagenicity, and indirect risks when a
conventional treatment is abandoned in favor of the natural
product. Furthermore, interactions between herbal medicines
and conventional drugs may be dangerous and can lead to
severe complications such as in the case of St John’s wort
(Hypericum perforatum) when given with other drugs
metabolized by P450 CYP3A4 (cyclosporine, coumarines).2
In renal medicine, among others,2,3 the most famous medicinal
plant-associated problem is Aristolochic-acid nephropathy
(Aristolochia fangchi), which has led to several cases of
end-stage renal failure all over the world.4
Therefore, research on medicinal plants as a source of new
substances is important; however, in humans, these compo-
nents should be administered only under well-controlled study
conditions. Furthermore, preliminary toxicological experiments
in cell cultures or animals would be desirable when such studies
are planned.
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